Efficacy and safety of combining anti-angiogenic therapy, radiotherapy, and PD-1 inhibitors in patients with driver gene-negative non-small cell lung cancer brain metastases: a retrospective study
Xianwen Zhang, Qian Sun, Rujun Chen, MengDie Zhao, Feng Cai, Zhen Cui, Hao Jiang · 2024
Read Efficacy and safety of combining anti-angiogenic therapy, radiotherapy, and PD-1 inhibitors in patients with driver gene-negative non-small cell lung cancer brain metastases: a retrospective study by Xianwen Zhang, Qian Sun, Rujun Chen, MengDie Zhao, Feng Cai, Zhen Cui, Hao Jiang (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11616174.txt.
Description
Zhang and six co-authors reviewed records in twenty twenty-four for lung cancer that had spread to the brain. All patients had non-small cell lung cancer without driver gene changes, and all got brain radiation plus PD-1 immune drugs. The question was whether adding a drug that blocks new blood vessel growth would help.
Eighty-eight patients treated between twenty twenty-one and twenty twenty-three were split by whether they also got the vessel-blocking therapy. The added-therapy group had far higher response rates inside the brain, about ninety-four percent versus sixty-three percent. Control of brain tumors also lasted longer. Overall survival, however, did not improve clearly. Blood pressure rises were more common with the added drug, but no brain bleeding from drugs occurred.
Catalog record
| CREATOR | Xianwen Zhang, Qian Sun, Rujun Chen, MengDie Zhao, Feng Cai, Zhen Cui, Hao Jiang |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |